Table 3.
Characteristics of adverse event reports for infigratinib
| Characteristics | N (%) |
|---|---|
| Age (year) | |
| < 18 | 2 (5.56) |
| 18–44 | 2 (5.56) |
| 45–64 | 8 (22.22) |
| 65–74 | 7 (19.44) |
| ≥ 75 | 3 (8.33) |
| Unknown | 14 (38.89) |
| Median (IQR) | 62.00 (49.50–70.50) |
| Sex | |
| Female | 21 (58.33) |
| Male | 11 (30.56) |
| Not specified | 4 (11.11) |
| Reporter country | |
| United States | 27 (75.00) |
| China | 3 (8.33) |
| Spain | 2 (5.56) |
| Belgium | 2 (5.56) |
| Puerto Rico | 1 (2.78) |
| Australia | 1 (2.78) |
| Outcomes | |
| Hospitalization (initial or prolonged) | 12 (33.33) |
| Other outcomes | 9 (25.00) |
| Unknown | 9 (25.00) |
| Death | 6 (16.67) |